Skip to main content

Retatrutide vs Semaglutide (Ozempic/Wegovy): 2026 Comparison

Last updated: June 25, 2026  |  Written by: Eric Sornoso, MealFan editor  |  Sources: Eli Lilly TRIUMPH-1 topline, NEJM Phase 2, SURMOUNT/STEP trials, FDA status June 2026.

Not medical advice. Retatrutide is investigational and not FDA approved as of June 2026. This is an editorial summary of public trial data. Consult a licensed clinician.
Short answer. Retatrutide (triple agonist) roughly doubles the weight loss of semaglutide (Ozempic/Wegovy, a single GLP-1 agonist) in the trial data — about 24–28% vs ~15%. But semaglutide is approved and widely available; retatrutide is investigational and ~2027–2028 away.
Average weight loss in clinical trials~24–28%Retatrutide~21%Tirzepatide~15%SemaglutideCross-trial comparison, not head-to-head. Illustrative.
Retatrutide’s three pathways drive markedly higher average loss than semaglutide’s one.

Key takeaways

  • Reta (~24-28%) roughly doubles semaglutide’s (~15%) weight loss in trials.
  • Semaglutide (Ozempic/Wegovy) is approved and available, including a pill form.
  • Reta acts on three receptors vs semaglutide’s one.
  • Semaglutide is the proven option you can start today.

One pathway vs three

Semaglutide acts on the GLP-1 receptor alone. Retatrutide adds GIP and glucagon. Each added pathway has tracked with more weight loss in trials — single (semaglutide) < dual (tirzepatide) < triple (retatrutide).

Retatrutide Semaglutide
Class Triple agonist GLP-1 agonist
Brands None yet Ozempic, Wegovy, Rybelsus
Avg weight loss ~24–28% (TRIUMPH-1) ~14.9% (STEP 1)
FDA status Investigational Approved

Bottom line

For a drug you can actually start, semaglutide (or tirzepatide) is the answer today. Retatrutide is the next-generation option to watch. The eating strategy doesn’t change between them — protein first, smaller meals, easy formats during escalation.

FAQ

Is retatrutide better than Ozempic or Wegovy?

On weight loss in the trial data, yes — roughly 24–28% vs ~15% for semaglutide. But it isn’t approved yet, so Wegovy remains the strongest available semaglutide option.

What’s the difference between a single, dual, and triple agonist?

Semaglutide hits one receptor (GLP-1), tirzepatide two (GLP-1/GIP), retatrutide three (adds glucagon). More pathways has tracked with more weight loss.

Should I wait for retatrutide instead of starting semaglutide?

That’s a medical decision — but note reta is likely 2027–2028 away. Many people don’t wait; they start an approved drug now and reassess later.

One pathway vs three, explained

Semaglutide is a clean, single-target GLP-1 drug, and that simplicity is part of why it has such a deep safety record. Retatrutide stacks GIP and glucagon on top of GLP-1. More targets has meant more weight loss across the class so far, but it also means more for the body to adjust to, which is why reta’s trials escalate the dose slowly.

Side effects, compared

Both are GI-dominant during dose escalation. Semaglutide’s profile is extremely well mapped after years of use; retatrutide’s is still trial-stage, with the added wrinkle that its glucagon component can lift heart rate slightly. For most people the lived experience early on – some nausea that fades – looks similar.

The oral question

Semaglutide already exists in pill form (Rybelsus, and higher-dose oral versions in development), which matters if you dislike injections. Retatrutide is injectable in its trials. If needle-aversion is a deal-breaker, that’s a point for the semaglutide family today.

Who each suits

Semaglutide is the proven, available, well-understood option – and the one you can actually start. Retatrutide is the higher-ceiling option on paper for people who need more weight loss than a single agonist delivers, but it’s still years from the pharmacy. The nutrition plan doesn’t change between them.

The nutrition side most drug guides skip

We are a food site, so here is what the drug-only sites leave out: retatrutide and semaglutide (Ozempic/Wegovy) works by shrinking appetite, and that creates a real nutritional risk. When you eat far less, you do not just lose fat – you can lose muscle and fall short on protein, fiber, and key vitamins and minerals. The fix is not eating more; it is making every bite count.

The four risks to manage (and the food fix)

Nutrition risk Why it happens The food fix
Muscle & protein loss Rapid weight loss plus too little protein – up to a third of lost weight can be lean muscle. 1.2-1.6 g protein per kg body weight daily; anchor every meal and snack with protein.
Low micronutrients Eating far less total food shrinks intake of iron, B12, calcium, vitamin D, potassium and magnesium. Nutrient-dense picks: eggs, salmon/sardines, Greek yogurt, leafy greens, beans, nuts and seeds, fortified foods.
Constipation Slowed digestion plus less food and fiber. Fiber-rich vegetables and fruit you can tolerate; steady fluids; move daily.
Dehydration & low energy Reduced intake and GI fluid losses during dose changes. Sip fluids and electrolytes through the day; never skip food entirely.

What to actually eat on retatrutide and semaglutide (Ozempic/Wegovy)

  • Protein at every meal and snack: eggs, chicken, fish, Greek yogurt, cottage cheese, tofu, beans, or a protein shake. When you can only finish a few bites, make them protein.
  • Nutrient-dense, smaller-volume foods: salmon and sardines (omega-3, vitamin D, B12), eggs, dairy, leafy greens, beans and lentils, nuts and seeds, berries.
  • Easy formats for nausea days: protein smoothies (protein powder + fruit + spinach), broth-based soups, yogurt.
  • Hydration and fiber: water and electrolytes through the day, plus tolerable high-fiber vegetables and fruit to keep things moving.

If your appetite is so low that you are eating very little, a daily multivitamin can backstop the gaps – ask your prescribing clinician. The goal across the board: protect muscle and stay nourished while the medication does its job.

The simplest way to hit these numbers while your appetite is unpredictable is pre-portioned, macro-labeled meal delivery built for exactly this.

See our tested GLP-1 meal delivery picks →
Or browse Best High-Protein Meal Delivery

Sources & references

Figures reflect Eli Lilly topline disclosures and peer-reviewed trial publications as of June 25, 2026. Retatrutide remains investigational; we will update on FDA action. Not medical advice.

Write a review × Browse menu
Write a review × Browse menu